Primary Objective: To develop create and maintain a pan-European multidisciplinary scientific network that will coordinate and enhance research and development (R&D) in the field of inhaled medicines with the aim to accelerate the development of a new generation of effective and safe inhaled medicines.
- To establish a roadmap to realistic computer simulations that will provide quantitative data to designers of aerosolized medicines and inhalation devices.
- To describe patient- and disease-specific biological interaction of inhaled particles within the lung.
- To promote advanced imaging technologies for patient monitoring, delivery verification and simulation validation.
- To promote integration of particle/formulation engineering with inhaler design for optimal lung delivery.
- To contribute to developing specifications and standards for aerosolized medicines that will accelerate and streamline transition from the R&D stage to approval.
- To identify and evaluate emerging technologies in the field and publish critical reviews that will be disseminated to end users (scientists, medical professionals, pharmaceutics companies).
- To identify commonalities with issues in inhaled pollutants.
- To promote the multidisciplinary / multisectorial training of Early Carreer Investigators (ECIs) in order to overcome fragmentation of knowledge in the field now, but also in the long term.
- To directly involve ECIs in outreach activities.
- To directly involve ECIs in the scientific deliberations of WGs.
- To generate new collaborations and ideas that will lead to new (independently funded) research projects.
- To deliver best-practice advice to practitioners and disseminate unbiased perspectives of scientific knowledge to decision makers, public authorities and other stakeholders.